Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
861.00    2.00 (0.23%)
Bid:
862.00
Ask:
864.00
Spread: 2.00 (0.232%)
Market Cap: £1.19b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

Replacement - Director/PDMR Shareholding

29 Apr 2026 15:04

RNS Number : 4489C
Savills PLC
29 April 2026
Β 

The following amendment has been made to the Director/PDMR Shareholding announcement released on 29 April 2026 at 13:23:26 under RNS #4417C:

Β 

The date of the vesting (28 April 2026) of Deferred Share Awards has been added to the introductory paragraph.

Β 

All other details remain unchanged.

Β 

The full amended text is shown below.

Β 

SAVILLS PLC (THE "COMPANY")

TRANSACTION IN SHARES BY DIRECTORS AND PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMRS)

Β 

Vesting of Deferred Share Awards

Β 

Awards over ordinary shares of the Company under the Company's Deferred Share Plans have become unconditional in all respects following the end of their Deferred Period. In satisfaction of the Awards, the Trustees of the Group's Employee Benefit Trusts have effected the transfer of shares on 28 April 2026, following the settlement of associated tax liabilities through the sale of shares, to Directors and PDMRs of the Company as follows:

Β 

Director/ PDMR

Number of shares transferred

Number of shares disposed to cover tax liabilities associated with award vesting

Shareholding following this notification

Shareholding as a % of issued share capital

Simon Shaw (Director)

48,468

43,468

(shares sold to cover tax liabilities associated with award vesting only)

276,793

0.19%

Martin Fidden (PDMR)

8,664

-

34,046

0.02%

Alex Jeffrey (PDMR)

53,143

-

292,074

0.20%

Chris Lee (PDMR)

9,774

8,710

(shares sold to cover tax liabilities associated with award vesting only)

133,311

0.09%

Raymond Lee (PDMR)

35,671

-

211,852

0.14%

David Lipson (PDMR)

30,333

-

175,760

0.12%

James Sparrow (PDMR)

42,767

38,106

(shares sold to cover tax liabilities associated with award vesting only)

170,884

0.12%

Β 

The share price on disposal of all shares was Β£8.405 per share.

Β 

Β 

Β 

Β 

Grant of Deferred Share Awards

Β 

The Company announces that on 28 April 2026 the grant of the share-based element of 2025 profit share awards has been made under The Savills Deferred Share Bonus Plan to Directors and PDMRs as follows:

Β 

Director/ PDMR

Number of shares subject to The Savills Deferred Share Bonus Plan awarded to the Director/ PDMR on 28 April 2026

Simon Shaw (Director)

111,077

Chris Lee (PDMR)

22,155

David Lipson (PDMR)

9,105

James Sparrow (PDMR)

63,832

These awards have a Deferred Period of three years and are subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Period to reflect final and interim dividends declared during the Deferred Period.

Β 

The Company also announces that on 28 April 2026 the grant of an award has been made under The Savills Deferred Share Plan (No.2 Plan) to the following PDMR:

PDMR

Number of shares subject to The Savills Deferred Share Plan (No.2 Plan) awarded to the PDMR on 28 April 2026

Martin Fidden (PDMR)

119,758

13% of the above award has a Deferred Period of two years51% of the above award has a Deferred Period of three years36% of the above award has a Deferred Period of four years

70% of the award with a Deferred Period of three years and 100% of the award with a Deferred Period of four years is subject to the satisfaction of performance criteria relating to the financial performance of the Savills Asia Pacific ex-Greater China business over 2025 to 2027 (inclusive).

All tranches of the award are subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Periods to reflect final and interim dividends declared during the Deferred Periods.

Β 

The Company also announces that on 28 April 2026 the grant of an award has been made under The Schedule to The Savills Deferred Share Plan (No.2 Plan) to a PDMR based in the United States of America as follows:

Β 

PDMR

Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on 28 April 2026

David Lipson (PDMR)

44,214

One-third of Mr Lipson's award will vest on each of the three anniversaries subsequent to the date of grant subject to continued employment and performance. The award is subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Period to reflect final and interim dividends declared during the Deferred Periods.

Β 

Resulting beneficial interests under The Savills Deferred Share Bonus Plan and The Savills Deferred Share Plan (No.2 Plan) further to the above notifications are as follows:

Director/ PDMR

Resulting beneficial interest under The Savills Deferred Share Bonus Plan and The Savills Deferred Share Plan (No.2 Plan)

Simon Shaw (Director)

237,302

Martin Fidden (PDMR)

65,870

Alex Jeffrey (PDMR)

75,287

Chris Lee (PDMR)

48,348

David Lipson (PDMR)

105,062

James Sparrow (PDMR)

138,914

Β 

The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.

1.

Details of the Director/ PDMR

Β 

(a)

Name

1. Simon Shaw

2. Martin Fidden

3. Alex Jeffrey

4. Chris Lee

5. Raymond Lee

6. David Lipson

7. James Sparrow

Β 

2.

Reason for the notification

Β 

(a)

Position/ status

1. Group Chief Executive/ Director

2. Chief Executive Officer - Asia Pacific (ex-Greater China)/ PDMR

3. Chief Executive Officer - Savills Investment Management/ PDMR

4. Group Legal Director & Company Secretary/ PDMR

5. Chief Executive - Hong Kong, Macau and Greater China/ PDMR

6. Chief Executive Officer - Savills North America/ PDMR

7. Chief Executive Officer - UK & EMEA/ PDMR

Β 

(b)

Initial notification/ Amendment

Β 

Initial notification

3.

Details of the issuer

Β 

(a)

Name

Savills plc

Β 

(b)

LEI

213800WXICGMBWHTA933

Β 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

(a)

Description of the Financial Instrument

Β 

Savills plc Ordinary Shares of 2.5p each

(b)

Identification code of the Financial Instrument

Β 

GB00B135BJ46

(c)

Nature of the transaction

Β 

1) Vesting of awards under the Company's Deferred Share Plans and sale of shares to cover tax liabilities associated with award vesting only

2) Grant of awards over Ordinary Shares in accordance with the Company's Deferred Share Plans

Β 

(d)

Price(s) and volume(s)

Β 

Price(s)

Volume(s)

Β 

1)

Acquisition

Β£nil per share

Β 

Β 

Β 

Β 

Β 

Disposal (to cover tax liabilities associated with award vesting only)

Β£8.405 per share

1. 92,253

2. 8,664

3. 53,143

4. 18,484

5. 35,671

6. 30,333

7. 80,873

Β 

1. 43,468

2. n/a

3. n/a

4. 8,710

5. n/a

6. n/a

7. 38,106

Β 

2)

Β£nil per share

1. 111,077

2. 119,758

3. n/a

4. 22,155

5. n/a

6. 53,316

7. 63,832

Β 

(e)

Aggregated information

Β 

- Aggregated volume

- Price

Β 

N/A

Β 

Β 

(f)

Date of the transaction

Β 

28 April 2026

(g)

Place of the transaction

Β 

Vesting of awards - Outside a trading venue

Β 

Sale of shares to cover tax liabilities associated with award vesting only - London Stock Exchange

Β 

Grant of awards - Outside a trading venue

Β 

Β 

Name of contact and telephone number for queries:

Chris Lee

Group Legal Director & Company Secretary

020 3107 5444

Β 

29 April 2026

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHUKRSRNUUSUAR
Date   Source Headline
11th Nov 20254:58 pmRNSDirector/PDMR Shareholding
3rd Nov 202512:32 pmRNSTotal Voting Rights
13th Oct 20251:33 pmRNSDirector/PDMR Shareholding
1st Oct 202511:00 amRNSTotal Voting Rights
29th Sep 202512:09 pmRNSDirector Declaration
25th Sep 20257:00 amRNSDirectorship Change
11th Sep 202512:38 pmRNSDirector/PDMR Shareholding
5th Sep 20252:00 pmRNSAdditional Listing
14th Aug 20257:00 amRNSHalf-year Report
12th Aug 20252:39 pmRNSDirector/PDMR Shareholding
1st Aug 20253:41 pmRNSHolding(s) in Company
21st Jul 20252:03 pmRNSBlock listing Interim Review
16th Jul 20251:44 pmRNSHolding(s) in Company
15th Jul 20254:20 pmRNSHolding(s) in Company
14th Jul 20251:14 pmRNSHolding(s) in Company
14th Jul 202510:18 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSTotal Voting Rights
30th Jun 20255:20 pmRNSDirector/PDMR Shareholding
23rd Jun 20252:45 pmRNSHolding(s) in Company
20th Jun 20254:00 pmRNSAdditional Listing
12th Jun 20258:15 amRNSDirector/PDMR Shareholding
12th Jun 20258:10 amRNSDirector/PDMR Shareholding
10th Jun 20255:57 pmRNSDirector/PDMR Shareholding
4th Jun 202512:12 pmRNSHolding(s) in Company
2nd Jun 20253:05 pmRNSHolding(s) in Company
2nd Jun 20258:58 amRNSHolding(s) in Company
22nd May 20255:31 pmRNSHolding(s) in Company
15th May 20254:06 pmRNSHolding(s) in Company
14th May 20252:38 pmRNSResult of AGM
14th May 20257:00 amRNSAGM Statement
13th May 20254:01 pmRNSDirector/PDMR Shareholding
29th Apr 20257:00 amRNSSavills Announces Succession Plan
7th Apr 20254:18 pmRNSAnnual Report and AGM Notice
1st Apr 202511:00 amRNSTotal Voting Rights
24th Mar 20252:18 pmRNSHolding(s) in Company
21st Mar 20253:00 pmRNSAdditional Listing
20th Mar 20259:21 amRNSDirector/PDMR Shareholding
18th Mar 20252:27 pmRNSHolding(s) in Company
13th Mar 20257:00 amRNSFinal Results
12th Mar 202511:00 amRNSDirector/PDMR Shareholding
17th Feb 20254:43 pmRNSBlock listing Interim Review
12th Feb 202511:10 amRNSDirector/PDMR Shareholding
11th Feb 20252:32 pmRNSHolding(s) in Company
7th Feb 20253:51 pmRNSHolding(s) in Company
3rd Feb 202511:00 amRNSTotal Voting Rights
29th Jan 20252:28 pmRNSHolding(s) in Company
28th Jan 20253:47 pmRNSHolding(s) in Company
22nd Jan 202511:47 amRNSBlock listing Interim Review
16th Jan 20257:00 amRNSYear End Trading Update
13th Jan 20252:35 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.